

Statement of unaudited financial results for the quarter and half year ended 30 September, 2020

(₹ in Millions)

| Particulars (Refer notes below) | Standalone (Ind AS) | | | | | | Consolidated (Ind AS) | | | | | |
|---|--|--|--|--|--|---------------------------------------|--|--|--|--|--|---------------------------------------|
| | Quarter Ended 30-09-2020 (Unaudited) | Quarter Ended 30-06-2020 (Unaudited) | Quarter Ended 30-09-2019 (Unaudited) | Half Year Ended 30-09-2020 (Unaudited) | Half Year Ended 30-09-2019 (Unaudited) | Year Ended 31-03-2020 (Audited) | Quarter Ended 30-09-2020 (Unaudited) | Quarter Ended 30-06-2020 (Unaudited) | Quarter Ended 30-09-2019 (Unaudited) | Half Year Ended 30-09-2020 (Unaudited) | Half Year Ended 30-09-2019 (Unaudited) | Year Ended 31-03-2020 (Audited) |
| I Revenue from operations | 20,254.92 | 16,524.45 | 17,426.23 | 36,779.37 | 31,978.56 | 64,912.00 | 29,081.18 | 23,092.83 | 27,637.31 | 52,174.01 | 50,473.35 | 103,972.28 |
| (a) Net sales | 366.73 | 304.77 | 471.96 | 671.50 | 907.56 | 2,214.31 | 443.61 | 355.04 | 513.09 | 798.65 | 905.84 | 2,437.41 |
| (b) Other operating income | 20,621.65 | 16,829.22 | 17,898.19 | 37,450.87 | 32,886.12 | 67,126.31 | 29,524.79 | 23,447.87 | 28,150.40 | 52,972.66 | 51,379.19 | 106,409.69 |
| II Total revenue from operations | 634.04 | 1,348.49 | 1,924.68 | 1,982.53 | 2,610.09 | 6,067.88 | (318.81) | 585.14 | 808.25 | 266.33 | 824.94 | 1,596.02 |
| III Total income (I + II) | 21,255.69 | 18,177.71 | 19,822.87 | 39,433.40 | 35,496.21 | 73,194.19 | 29,205.98 | 24,033.01 | 28,958.65 | 53,238.99 | 52,204.13 | 108,005.71 |
| IV Expenses | 7,503.36 | 5,917.41 | 5,675.87 | 13,420.77 | 10,869.60 | 22,519.81 | 8,648.40 | 7,041.92 | 6,466.53 | 15,690.32 | 12,552.58 | 25,414.74 |
| (a) Cost of materials consumed | 658.51 | 762.73 | 928.73 | 1,421.24 | 1,894.86 | 3,652.41 | 2,976.78 | 217.83 | 2,788.10 | 3,194.61 | 5,375.10 | 10,290.83 |
| (b) Purchases of stock-in-trade | 41.63 | (157.24) | 196.85 | (115.61) | 104.01 | 487.68 | (1,218.03) | 823.91 | 606.86 | (394.12) | 34.83 | 1,280.82 |
| (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | 3,375.76 | 2,372.36 | 3,457.94 | 5,748.12 | 5,658.10 | 10,723.27 | 7,002.54 | 5,096.06 | 6,866.00 | 12,098.60 | 11,732.90 | 22,547.76 |
| (d) Employee benefits expense | 604.12 | 599.38 | 651.67 | 1,203.50 | 1,332.43 | 2,563.90 | 806.32 | 937.40 | 897.71 | 1,743.72 | 1,827.86 | 3,773.18 |
| (e) Finance costs | 367.94 | 358.09 | 333.22 | 726.03 | 654.87 | 1,385.38 | 1,040.65 | 1,132.22 | 941.61 | 2,172.87 | 1,848.92 | 4,171.66 |
| (f) Depreciation, amortisation and impairment expense | 4,088.84 | 2,846.52 | 3,833.52 | 6,935.36 | 7,467.83 | 16,700.84 | 6,586.97 | 5,487.47 | 6,918.83 | 12,074.44 | 13,760.58 | 29,894.72 |
| (g) Other expenses | 16,640.16 | 12,699.25 | 15,077.80 | 29,339.41 | 27,981.70 | 58,033.29 | 25,843.63 | 20,736.81 | 25,485.64 | 46,580.44 | 47,132.77 | 97,373.71 |
| Total expenses (IV) | 4,615.53 | 5,478.46 | 4,745.07 | 10,093.99 | 7,514.51 | 15,160.90 | 3,362.35 | 3,296.20 | 3,473.01 | 6,658.55 | 5,071.36 | 10,632.00 |
| V Profit/(loss) before exceptional items and tax (III - IV) | 0.00 | (279.90) | - | (279.90) | - | (185.54) | (31.40) | (279.90) | - | (311.30) | - | (328.76) |
| VI Exceptional items (gain) (Refer note 6) | 4,615.53 | 5,758.36 | 4,745.07 | 10,373.89 | 7,514.51 | 15,346.44 | 3,393.75 | 3,576.10 | 3,473.01 | 6,969.85 | 5,071.36 | 10,960.76 |
| VII Profit/(loss) before tax (V - VI) | - | - | - | - | - | - | - | - | - | - | - | - |
| VIII Tax expense: | 802.53 | 1,012.33 | 713.19 | 1,814.86 | 1,317.96 | 2,692.37 | 1,367.28 | 1,322.78 | 1,030.15 | 2,690.06 | 1,989.77 | 3,961.27 |
| Current tax | (215.76) | (121.28) | (288.04) | (94.48) | (891.41) | (313.46) | (287.10) | (287.10) | (112.56) | (600.56) | (566.64) | (760.21) |
| IX Profit/(loss) for the period from continuing operations (VII - VIII) | 4,028.76 | 4,624.75 | 4,319.92 | 8,653.51 | 6,598.35 | 13,545.48 | 2,339.93 | 2,540.42 | 2,555.42 | 4,880.35 | 3,648.23 | 7,759.70 |
| X Profit/(loss) before tax from discontinuing operations | - | - | - | - | - | - | - | - | - | - | - | - |
| XI Tax expense of discontinuing operations: | - | - | - | - | - | - | - | - | - | - | - | - |
| Current tax | - | - | - | - | - | - | - | - | - | - | - | - |
| Deferred tax | - | - | - | - | - | - | - | - | - | - | - | - |
| XII Profit/(loss) for the period from discontinuing operations (X - XI) | - | - | - | - | - | - | - | - | - | - | - | - |
| XIII Profit/(loss) for the period for continuing and discontinuing operations (IX + XII) | 4,028.76 | 4,624.75 | 4,319.92 | 8,653.51 | 6,598.35 | 13,545.48 | 2,339.93 | 2,540.42 | 2,555.42 | 4,880.35 | 3,648.23 | 7,759.70 |
| XIV Other comprehensive income | 5.44 | 5.51 | (43.72) | 10.95 | (25.69) | (88.83) | (137.89) | 0.37 | (164.35) | (137.52) | (202.60) | 52.52 |
| A (i) Items that will not be reclassified to profit or loss | (1.90) | (1.93) | 14.04 | (3.83) | 8.47 | 34.61 | 15.72 | (0.38) | 29.86 | 15.34 | 31.08 | 15.08 |
| (ii) Income tax relating to items that will not be reclassified to profit or loss | - | - | - | - | - | - | (291.15) | 259.62 | (947.49) | (31.53) | (535.39) | (2,248.33) |
| B (i) Items that will be reclassified to profit or loss | - | - | - | - | - | - | - | - | - | - | - | - |
| (ii) Income tax relating to items that will be reclassified to profit or loss | - | - | - | - | - | - | - | - | - | - | - | - |
| XV Total comprehensive income | 4,032.30 | 4,628.33 | 4,290.24 | 8,660.63 | 6,581.13 | 13,491.26 | 2,142.26 | 2,782.38 | 1,391.47 | 4,924.64 | 2,884.06 | 60,422.88 |
| XVI Total comprehensive income attributable to: | - | - | - | - | - | - | (0.43) | 1.33 | 0.47 | 0.90 | 0.75 | 0.03 |
| - Non-controlling interests | - | - | - | - | - | - | - | - | - | - | - | - |
| - Owners of the Company | 4,032.30 | 4,628.33 | 4,290.24 | 8,660.63 | 6,581.13 | 13,491.26 | 2,142.26 | 2,782.38 | 1,391.47 | 4,924.64 | 2,884.06 | 60,422.88 |
| XVII Other equity | - | - | - | - | - | - | - | - | - | - | - | - |
| XVIII Earning per share (EPS) (for continuing operations) (of Re 1/- each) (not annualised)* | 14.28 | 16.39 | 15.31 | 30.67 | 23.38 | 48.00 | 8.29 | 9.00 | 9.06 | 17.30 | 12.93 | 27.50 |
| Basic EPS (in Rupees) | 14.28 | 16.39 | 15.31 | 30.67 | 23.38 | 48.00 | 8.29 | 9.00 | 9.06 | 17.30 | 12.93 | 27.50 |
| Diluted EPS (in Rupees) | - | - | - | - | - | - | - | - | - | - | - | - |
| XIX Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)* | - | - | - | - | - | - | - | - | - | - | - | - |
| Basic EPS (in Rupees) | - | - | - | - | - | - | - | - | - | - | - | - |
| Diluted EPS (in Rupees) | - | - | - | - | - | - | - | - | - | - | - | - |
| XX Earning per share (EPS) (for continuing and discontinuing operations) (of Re 1/- each) (not annualised)* | 14.28 | 16.39 | 15.31 | 30.67 | 23.38 | 48.00 | 8.29 | 9.00 | 9.06 | 17.30 | 12.93 | 27.50 |
| Basic EPS (in Rupees) | 14.28 | 16.39 | 15.31 | 30.67 | 23.38 | 48.00 | 8.29 | 9.00 | 9.06 | 17.30 | 12.93 | 27.50 |
| Diluted EPS (in Rupees) | - | - | - | - | - | - | - | - | - | - | - | - |

* except for the year ended 31 March 2020

Glenmark Pharmaceuticals Limited

Statement of assets and liabilities
(All amounts in million of Indian Rupees, unless otherwise stated)

| Particulars | STANDALONE | | CONSOLIDATED | |
|--|---|---------------------------------------|---|---------------------------------------|
| | Ind AS As at 30.09.2020 Unaudited | Ind AS As at 31.03.2020 Audited | Ind AS As at 30.09.2020 Unaudited | Ind AS As at 31.03.2020 Audited |
| ASSETS | | | | |
| Non current assets | | | | |
| Property, plant and equipment | 14,817.15 | 14,688.16 | 29,453.85 | 29,777.08 |
| Capital work-in-progress | 1,042.78 | 1,524.97 | 11,280.58 | 10,906.36 |
| Goodwill | - | - | 558.20 | 528.99 |
| Other intangible assets | 1,353.05 | 1,431.29 | 21,074.40 | 19,979.48 |
| Intangible assets under development | 1,468.05 | 475.17 | 1,681.87 | 1,312.50 |
| Financial assets | | | | |
| (i) Investments | 47,249.23 | 47,139.29 | 246.00 | 245.91 |
| (ii) Loans | 76,617.02 | 71,155.46 | - | - |
| (iii) Other financial assets | 333.65 | 268.80 | 713.63 | 655.79 |
| Deferred tax assets (net) | 8,138.00 | 8,047.35 | 15,022.68 | 14,557.05 |
| Other non-current assets | 525.78 | 546.53 | 1,081.32 | 848.75 |
| Total non-current assets | 151,544.71 | 145,277.02 | 81,112.53 | 78,811.91 |
| Current assets | | | | |
| Inventories | 8,097.11 | 8,375.02 | 22,025.01 | 21,356.24 |
| Financial assets | | | | |
| (i) Investments | - | - | - | - |
| (ii) Trade receivables | 20,454.24 | 18,352.40 | 26,479.90 | 24,089.62 |
| (iii) Cash and cash equivalents | 419.78 | 872.92 | 8,872.94 | 11,102.75 |
| (iv) Bank balance other than cash and cash equivalents | 8.24 | 9.67 | 8.24 | 9.67 |
| (v) Other financial assets | 10,747.91 | 11,191.99 | 1,398.12 | 1,249.44 |
| Current tax assets | 5,872.05 | 5,436.97 | 11,018.42 | 10,228.44 |
| Other current assets | 45,599.33 | 44,238.97 | 69,802.63 | 68,036.16 |
| Total current assets | 197,144.04 | 189,515.99 | 150,915.16 | 146,848.07 |
| EQUITY AND LIABILITIES | | | | |
| Equity | | | | |
| Equity share capital | 282.17 | 282.17 | 282.17 | 282.17 |
| Other equity | 139,963.50 | 131,980.47 | 64,670.03 | 60,422.88 |
| Non-controlling interests | - | - | (3.11) | (3.92) |
| Liabilities | | | | |
| Non-current liabilities | | | | |
| Financial liabilities | | | | |
| (i) Borrowings | 16,542.04 | 31,311.66 | 25,959.00 | 40,429.94 |
| (ii) Other financial liabilities | 1,960.20 | 2,056.51 | 4,332.44 | 4,288.01 |
| Deferred tax liabilities (net) | - | - | 196.82 | 164.48 |
| Other non-current liabilities | - | - | 7.76 | 4.68 |
| Total non-current liabilities | 18,502.24 | 33,368.17 | 30,496.02 | 44,887.11 |
| Current liabilities | | | | |
| Financial liabilities | | | | |
| (i) Borrowings | 3,627.16 | 4,425.97 | 3,627.16 | 4,425.97 |
| (ii) Other financial liabilities | 16,490.56 | 2,035.95 | 21,317.17 | 8,583.66 |
| (iii) Trade payables | - | - | - | - |
| - Total outstanding dues of Micro enterprises and Small enterprises | 621.01 | 748.82 | 804.19 | 849.48 |
| - Total outstanding dues of other than Micro enterprises and Small enterprises | 14,869.55 | 15,107.15 | 20,512.98 | 7,734.18 |
| Other current liabilities | 282.67 | 388.25 | 1,191.80 | 1,432.65 |
| Provisions | 1,769.42 | 1,024.04 | 6,491.32 | 5,151.99 |
| Current tax liabilities (net) | 798.49 | 160.44 | 1,171.88 | 407.13 |
| Total current liabilities | 38,396.13 | 23,885.18 | 55,470.05 | 41,259.83 |
| Total liabilities | 56,898.37 | 57,253.35 | 85,966.07 | 86,146.94 |
| Total equity and liabilities | 197,144.04 | 189,515.99 | 150,915.16 | 146,848.07 |

Glenmark Pharmaceuticals Limited

Consolidated statement of cash flows for the half year ended 30 September, 2020
(All amounts in million of Indian Rupees, unless otherwise stated)

| Particulars | Half Year Ended 30-09-2020 (Unaudited) | Half Year Ended 30-09-2019 (Unaudited) |
|---|--|--|
| | (A) Cash flow from operating activities | |
| Profit before tax | 6,969.85 | 5,071.37 |
| Adjustments to reconcile profit before tax to net cash provided by operating activities: | | |
| Depreciation, impairment and amortisation | 2,172.87 | 1,848.92 |
| Finance costs | 1,743.72 | 1,827.86 |
| Interest income | (9.70) | (27.76) |
| (Profit)/loss on sale of property, plant and equipments | 26.18 | (1.13) |
| Fair valuation of Investment | (0.09) | - |
| Employee benefit obligation | 407.59 | 197.96 |
| Provision for doubtful debts / expected credit losses | 0.09 | 100.14 |
| Employee share based compensation expense | 27.81 | 22.37 |
| Exceptional item | (311.30) | - |
| Unrealised foreign exchange (gain) | (245.89) | (208.32) |
| Operating profit before working capital changes | 10,781.13 | 8,831.41 |
| Changes in operating assets and liabilities | | |
| - (Increase)/ Decrease in trade receivables | (2,334.88) | 869.82 |
| - (Increase) / Decrease in inventories | (321.72) | 800.66 |
| - (Increase)/ Decrease in other assets | (1,402.41) | (816.83) |
| - Increase/(Decrease) in trade payable and other liabilities | (537.85) | (1,728.63) |
| Cash generated from operations | 6,184.27 | 7,956.43 |
| Income taxes paid | (1,945.27) | (2,089.47) |
| Net cash generated from operating activities | 4,239.00 | 5,866.96 |
| (B) Cash flow from investing activities | | |
| (Increase)/ Decrease in restricted cash | 1.39 | 707.74 |
| Interest received | 13.90 | 29.32 |
| Payments for Purchase of Property, plant and equipment and Intangible assets (including Capital work in progress) | (4,159.75) | (5,122.75) |
| Proceeds from sale of Property, plant and equipment, Intangible assets and brands, business (disc | | |

Statement of unaudited financial results for the quarter and half year ended 30 September, 2020

| Particulars (Refer notes below) | Standalone (Ind AS) | | | | | | Consolidated (Ind AS) | | | | | | |
|---|--|--|--|--|--|---------------------------------------|--|--|--|--|--|---------------------------------------|--|
| | Quarter Ended 30-09-2020 (Unaudited) | Quarter Ended 30-06-2020 (Unaudited) | Quarter Ended 30-09-2019 (Unaudited) | Half Year Ended 30-09-2020 (Unaudited) | Half Year Ended 30-09-2019 (Unaudited) | Year Ended 31-03-2020 (Audited) | Quarter Ended 30-09-2020 (Unaudited) | Quarter Ended 30-06-2020 (Unaudited) | Quarter Ended 30-09-2019 (Unaudited) | Half Year Ended 30-09-2020 (Unaudited) | Half Year Ended 30-09-2019 (Unaudited) | Year Ended 31-03-2020 (Audited) | |
| | (₹ in Millions) | | | | | | | | | | | | |
| I Revenue from operations | | | | | | | | | | | | | |
| (a) Net sales | 20,254.92 | 16,524.45 | 17,426.23 | 36,779.37 | 31,978.56 | 64,912.00 | 29,081.18 | 23,092.83 | 27,637.31 | 52,174.01 | 50,473.35 | 103,972.28 | |
| (b) Other operating income | 366.73 | 304.77 | 471.96 | 671.50 | 907.56 | 2,214.31 | 443.61 | 355.04 | 513.09 | 798.65 | 905.84 | 2,437.41 | |
| Total revenue from operations | 20,621.65 | 16,829.22 | 17,898.19 | 37,450.87 | 32,886.12 | 67,126.31 | 29,524.79 | 23,447.87 | 28,150.40 | 52,972.66 | 51,379.19 | 106,409.69 | |
| II Other income | 634.04 | 1,348.49 | 1,924.68 | 1,982.53 | 2,610.09 | 6,067.88 | (318.81) | 585.14 | 808.25 | 266.33 | 824.94 | 1,596.02 | |
| III Total income (I + II) | 21,255.69 | 18,177.71 | 19,822.87 | 39,433.40 | 35,496.21 | 73,194.19 | 29,205.98 | 24,033.01 | 28,958.65 | 53,238.99 | 52,204.13 | 108,005.71 | |
| IV Expenses | | | | | | | | | | | | | |
| (a) Cost of materials consumed | 7,503.36 | 5,917.41 | 5,675.87 | 13,420.77 | 10,869.60 | 22,519.81 | 8,648.40 | 7,041.92 | 6,466.53 | 15,690.32 | 12,552.58 | 25,414.74 | |
| (b) Purchases of stock-in-trade | 658.51 | 762.73 | 928.73 | 1,421.24 | 1,894.86 | 3,652.41 | 2,976.78 | 217.83 | 2,788.10 | 3,194.61 | 5,375.10 | 10,290.83 | |
| (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | 41.63 | (157.24) | 196.85 | (115.61) | 104.01 | 487.68 | (1,218.03) | 823.91 | 606.86 | (394.12) | 34.83 | 1,280.82 | |
| (d) Employee benefits expense | 3,375.76 | 2,372.36 | 3,457.94 | 5,748.12 | 5,658.10 | 10,723.27 | 7,002.54 | 5,096.06 | 6,866.00 | 12,098.60 | 11,732.90 | 22,547.76 | |
| (e) Finance costs | 604.12 | 599.38 | 651.67 | 1,203.50 | 1,332.43 | 2,563.90 | 806.32 | 937.40 | 897.71 | 1,743.72 | 1,827.86 | 3,773.18 | |
| (f) Depreciation, amortisation and impairment expense | 367.94 | 358.09 | 333.22 | 726.03 | 654.87 | 1,385.38 | 1,040.65 | 1,132.22 | 941.61 | 2,172.87 | 1,848.92 | 4,171.66 | |
| (g) Other expenses | 4,088.84 | 2,846.52 | 3,833.52 | 6,935.36 | 7,467.83 | 16,700.84 | 6,586.97 | 5,487.47 | 6,918.83 | 12,074.44 | 13,760.58 | 29,894.72 | |
| Total expenses (IV) | 16,640.16 | 12,699.25 | 15,077.80 | 29,339.41 | 27,981.70 | 58,033.29 | 25,843.63 | 20,736.81 | 25,485.64 | 46,580.44 | 47,132.77 | 97,373.71 | |
| V Profit/(loss) before exceptional items and tax (III - IV) | 4,615.53 | 5,478.46 | 4,745.07 | 10,093.99 | 7,514.51 | 15,160.90 | 3,362.35 | 3,296.20 | 3,473.01 | 6,658.55 | 5,071.36 | 10,632.00 | |
| VI Exceptional items (gain) (Refer note 6) | 0.00 | (279.90) | - | (279.90) | - | (185.54) | (31.40) | (279.90) | - | (311.30) | - | (328.76) | |
| VII Profit/(loss) before tax (V - VI) | 4,615.53 | 5,758.36 | 4,745.07 | 10,373.89 | 7,514.51 | 15,346.44 | 3,393.75 | 3,576.10 | 3,473.01 | 6,969.85 | 5,071.36 | 10,960.76 | |
| VIII Tax expense: | | | | | | | | | | | | | |
| Current tax | 802.53 | 1,012.33 | 1,713.19 | 1,814.86 | 1,317.96 | 2,692.37 | 1,367.28 | 1,322.78 | 1,030.15 | 2,690.06 | 1,989.77 | 3,961.27 | |
| Deferred tax | (215.76) | 121.28 | (288.04) | (94.48) | (401.80) | (891.41) | (313.46) | (287.10) | (112.56) | (600.56) | (566.64) | (760.21) | |
| IX Profit/(loss) for the period from continuing operations (VII - VIII) | 4,028.76 | 4,624.75 | 4,319.92 | 8,653.51 | 6,598.35 | 13,545.48 | 2,339.93 | 2,540.42 | 2,555.42 | 4,880.35 | 3,648.23 | 7,759.70 | |
| X Profit/(loss) before tax from discontinuing operations | - | - | - | - | - | - | - | - | - | - | - | - | |
| XI Tax expense of discontinuing operations: | | | | | | | | | | | | | |
| Current tax | - | - | - | - | - | - | - | - | - | - | - | - | |
| Deferred tax | - | - | - | - | - | - | - | - | - | - | - | - | |
| XII Profit/(loss) for the period from discontinuing operations (X - XI) | - | - | - | - | - | - | - | - | - | - | - | - | |
| XIII Profit/(loss) for the period for continuing and discontinuing operations (IX + XII) | 4,028.76 | 4,624.75 | 4,319.92 | 8,653.51 | 6,598.35 | 13,545.48 | 2,339.93 | 2,540.42 | 2,555.42 | 4,880.35 | 3,648.23 | 7,759.70 | |
| XIV Other comprehensive income | | | | | | | | | | | | | |
| A (i) Items that will not be reclassified to profit or loss | 5.44 | 5.51 | (43.72) | 10.95 | (25.69) | (88.83) | (137.89) | 0.37 | (164.35) | (137.52) | (202.60) | 52.52 | |
| (ii) Income tax relating to items that will not be reclassified to profit or loss | (1.90) | (1.93) | 14.04 | (3.83) | 8.47 | 34.61 | 15.72 | (0.38) | 29.86 | 15.34 | 31.08 | 15.08 | |
| B (i) Items that will be reclassified to profit or loss | - | - | - | - | - | - | (291.15) | 259.62 | (947.49) | (31.53) | (535.39) | (2,248.33) | |
| (ii) Income tax relating to items that will be reclassified to profit or loss | - | - | - | - | - | - | 215.22 | (16.32) | (81.50) | 198.90 | (56.51) | (276.42) | |
| XV Total comprehensive income | 4,032.30 | 4,628.33 | 4,290.24 | 8,660.63 | 6,581.13 | 13,491.26 | 2,141.83 | 2,783.71 | 1,391.94 | 4,925.54 | 2,884.81 | 5,302.55 | |
| XVI Total comprehensive income attributable to: | | | | | | | | | | | | | |
| - Non-controlling interests | - | - | - | - | - | - | (0.43) | 1.33 | 0.47 | 0.90 | 0.75 | 0.03 | |
| - Owners of the Company | 4,032.30 | 4,628.33 | 4,290.24 | 8,660.63 | 6,581.13 | 13,491.26 | 2,142.26 | 2,782.38 | 1,391.47 | 4,924.64 | 2,884.06 | 5,302.52 | |
| XVII Other equity | - | - | - | - | - | 131,980.47 | - | - | - | - | - | 60,422.88 | |
| XVIII Earning per share (EPS) (for continuing operations) (of Re 1/- each) (not annualised)* | | | | | | | | | | | | | |
| Basic EPS (in Rupees) | 14.28 | 16.39 | 15.31 | 30.67 | 23.38 | 48.00 | 8.29 | 9.00 | 9.06 | 17.30 | 12.93 | 27.50 | |
| Diluted EPS (in Rupees) | 14.28 | 16.39 | 15.31 | 30.67 | 23.38 | 48.00 | 8.29 | 9.00 | 9.06 | 17.30 | 12.93 | 27.50 | |
| XIX Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)* | | | | | | | | | | | | | |
| Basic EPS (in Rupees) | - | - | - | - | - | - | - | - | - | - | - | - | |
| Diluted EPS (in Rupees) | - | - | - | - | - | - | - | - | - | - | - | - | |
| XX Earning per share (EPS) (for continuing and discontinuing operations) (of Re 1/- each) (not annualised)* | | | | | | | | | | | | | |
| Basic EPS (in Rupees) | 14.28 | 16.39 | 15.31 | 30.67 | 23.38 | 48.00 | 8.29 | 9.00 | 9.06 | 17.30 | 12.93 | 27.50 | |
| Diluted EPS (in Rupees) | 14.28 | 16.39 | 15.31 | 30.67 | 23.38 | 48.00 | 8.29 | 9.00 | 9.06 | 17.30 | 12.93 | 27.50 | |

* except for the year ended 31 March 2020

Glenmark Pharmaceuticals Limited

Statement of assets and liabilities

(All amounts in million of Indian Rupees, unless otherwise stated)

| Particulars | STANDALONE | | CONSOLIDATED | |
|--|---|---------------------------------------|---|---------------------------------------|
| | Ind AS As at 30.09.2020 Unaudited | Ind AS As at 31.03.2020 Audited | Ind AS As at 30.09.2020 Unaudited | Ind AS As at 31.03.2020 Audited |
| | ASSETS | | | |
| Non current assets | | | | |
| Property, plant and equipment | 14,817.15 | 14,688.16 | 29,453.85 | 29,777.08 |
| Capital work-in-progress | 1,042.78 | 1,524.97 | 11,280.58 | 10,906.36 |
| Goodwill | - | - | 558.20 | 528.99 |
| Other intangible assets | 1,353.05 | 1,431.29 | 21,074.40 | 19,979.48 |
| Intangible assets under development | 1,468.05 | 475.17 | 1,681.87 | 1,312.50 |
| Financial assets | | | | |
| (i) Investments | 47,249.23 | 47,139.29 | 246.00 | 245.91 |
| (ii) Loans | 76,617.02 | 71,155.46 | - | - |
| (iii) Other financial assets | 333.65 | 268.80 | 713.63 | 655.79 |
| Deferred tax assets (net) | 8,138.00 | 8,047.35 | 15,022.68 | 14,557.05 |
| Other non-current assets | 525.78 | 546.53 | 1,081.32 | 848.75 |
| Total non-current assets | 151,544.71 | 145,277.02 | 81,112.53 | 78,811.91 |
| Current assets | | | | |
| Inventories | 8,097.11 | 8,375.02 | 22,025.01 | 21,356.24 |
| Financial assets | | | | |
| (i) Investments | - | - | - | - |
| (ii) Trade receivables | 20,454.24 | 18,352.40 | 26,479.90 | 24,089.62 |
| (iii) Cash and cash equivalents | 419.78 | 872.92 | 8,872.94 | 11,102.75 |
| (iv) Bank balance other than cash and cash equivalents | 8.24 | 9.67 | 8.24 | 9.67 |
| (v) Other financial assets | 10,747.91 | 11,191.99 | 1,398.12 | 1,249.44 |
| Current tax assets | - | - | - | - |
| Other current assets | 5,872.05 | 5,436.97 | 11,018.42 | 10,228.44 |
| Total current assets | 45,599.33 | 44,238.97 | 69,802.63 | 68,036.16 |
| Total assets | 197,144.04 | 189,515.99 | 150,915.16 | 146,848.07 |
| EQUITY AND LIABILITIES | | | | |
| Equity | | | | |
| Equity share capital | 282.17 | 282.17 | 282.17 | 282.17 |
| Other equity | 139,963.50 | 131,980.47 | 64,670.03 | 60,422.88 |
| Non-controlling interests | - | - | (3.11) | (3.92) |
| Liabilities | | | | |
| Non-current liabilities | | | | |
| Financial liabilities | | | | |
| (i) Borrowings | 16,542.04 | 31,311.66 | 25,959.00 | 40,429.94 |
| (ii) Other financial liabilities | 1,960.20 | 2,056.51 | 4,332.44 | 4,288.01 |
| Deferred tax liabilities (net) | - | - | 196.82 | 164.48 |
| Other non-current liabilities | - | - | 7.76 | 4.68 |
| Total non-current liabilities | 18,502.24 | 33,368.17 | 30,496.02 | 44,887.11 |
| Current liabilities | | | | |
| Financial liabilities | | | | |
| (i) Borrowings | 3,627.16 | 4,425.97 | 3,627.16 | 4,425.97 |
| (ii) Other financial liabilities | 16,490.56 | 2,035.95 | 21,317.17 | 8,583.66 |
| (iii) Trade payables | - | - | - | - |
| - Total outstanding dues of Micro enterprises and Small enterprises | 621.01 | 748.82 | 804.19 | 849.48 |
| - Total outstanding dues of other than Micro enterprises and Small enterprises | 14,869.85 | 15,101.71 | 20,866.53 | 20,408.95 |
| Other current liabilities | 282.67 | 388.25 | 1,191.80 | 1,432.65 |
| Provisions | 1,769.42 | 1,024.04 | 6,491.32 | 5,151.99 |
| Current tax liabilities (net) | 798.49 | 160.44 | 1,171.88 | 407.13 |
| Total current liabilities | 38,396.13 | 23,885.18 | 55,470.05 | 41,259.83 |
| Total liabilities | 56,898.37 | 57,253.35 | 85,966.07 | 86,146.94 |
| Total equity and liabilities | 197,144.04 | 189,515.99 | 150,915.16 | 146,848.07 |

Glenmark Pharmaceuticals Limited

Consolidated statement of cash flows for the half year ended 30 September, 2020

(All amounts in million of Indian Rupees, unless otherwise stated)

| Particulars | Half Year Ended 30-09-2020 (Unaudited) | Half Year Ended 30-09-2019 (Unaudited) |
|---|--|--|
| | (A) Cash flow from operating activities | |
| Profit before tax | 6,969.85 | 5,071.37 |
| Adjustments to reconcile profit before tax to net cash provided by operating activities: | | |
| Depreciation, impairment and amortisation | 2,172.87 | 1,848.92 |
| Finance costs | 1,743.72 | 1,827.86 |
| Interest income | (9.70) | (27.76) |
| (Profit)/loss on sale of property, plant and equipments | 26.18 | (1.13) |
| Fair valuation of Investment | (0.09) | - |
| Employee benefit obligation | 407.59 | 197.96 |
| Provision for doubtful debts / expected credit losses | 0.09 | 100.14 |
| Employee share based compensation expense | 27.81 | 22.37 |
| Exceptional item | (311.30) | - |
| Unrealised foreign exchange (gain) | (245.89) | (208.32) |
| Operating profit before working capital changes | 10,781.13 | 8,831.41 |
| Changes in operating assets and liabilities | | |
| - (Increase) / Decrease in trade receivables | (2,334.88) | 869.82 |
| - (Increase) / Decrease in inventories | (3,021.72) | 800.66 |
| - (Increase) / Decrease in other assets | (1,402.41) | (816.83) |
| - Increase / (Decrease) in trade payable and other liabilities | (537.85) | (1,728.63) |
| Cash generated from operations | 6,184.27 | 7,956.43 |
| Income taxes paid | (1,945.27) | (2,089.47) |
| Net cash generated from operating activities | 4,239.00 | 5,866.96 |
| (B) Cash flow from investing activities | | |
| (Increase) / Decrease in restricted cash | 1.39 | 707.74 |
| Interest received | 13.90 | 29.32 |
| Payments for Purchase of Property, plant and equipment and Intangible assets (including Capital work in progress) | (4,159.75) | (5,122.75) |
| Proceeds from sale of Property, plant and equipment, Intangible assets and brands, business (disclosed as exceptional item) | 425.82 | 208.45 |
| Net cash used in investing activities | (3,718.64) | (4,177.24) |
| (C) Cash flow from financing activities | | |
| Proceeds from long-term borrowings | 1,719.71 | 2,096.70 |
| Repayments of long-term borrowings | (2,430.03) | (2,620.88) |
| Proceeds from / (repayment) of short-term borrowings (net) | (560.62) | 1,128.91 |
| Interest paid | (1,271.46) | (1,561.41) |
| Payment of lease liabilities | (464.72) | (219.46) |
| Dividend paid (including tax on dividend) | (1.43) | (2.42) |
| Net cash used in financing activities | (3,008.55) | (1,178.56) |
| Effect of exchange rate changes on cash and cash equivalents | 258.38 | (710.43) |
| Net increase/(decrease) in cash and cash equivalents | (2,229.81) | (199.27) |
| Opening balance of cash and cash equivalents | 11,102.75 | 9,362. |